A case of erythema nodosum concomitant with ulcerative colitis relieved by tofacitinib

Dermatologic TherapyVolume 35, Issue 12 e15963 LETTER A case of erythema nodosum concomitant with ulcerative colitis relieved by tofacitinib Kanae Nakamura, Kanae Nakamura orcid.org/0000-0002-3125-0972 Department of Dermatology, Fukuoka University Faculty of Medicine, Fukuoka, JapanSearch for more papers by this authorEmi Sato, Corresponding Author Emi Sato [email protected] orcid.org/0000-0001-9394-653X Department of Dermatology, Fukuoka University Faculty of Medicine, Fukuoka, Japan Correspondence Emi Sato, Department of Dermatology, Fukuoka University Faculty of Medicine, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan. Email: [email protected]Search for more papers by this authorShinichi Imafuku, Shinichi Imafuku orcid.org/0000-0001-8568-4349 Department of Dermatology, Fukuoka University Faculty of Medicine, Fukuoka, JapanSearch for more papers by this author Kanae Nakamura, Kanae Nakamura orcid.org/0000-0002-3125-0972 Department of Dermatology, Fukuoka University Faculty of Medicine, Fukuoka, JapanSearch for more papers by this authorEmi Sato, Corresponding Author Emi Sato [email protected] orcid.org/0000-0001-9394-653X Department of Dermatology, Fukuoka University Faculty of Medicine, Fukuoka, Japan Correspondence Emi Sato, Department of Dermatology, Fukuoka University Faculty of Medicine, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan. Email: [email protected]Search for more papers by this authorShinichi Imafuku, Shinichi Imafuku orcid.org/0000-0001-8568-4349 Department of Dermatology, Fukuoka University Faculty of Medicine, Fukuoka, JapanSearch for more papers by this author First published: 10 November 2022 https://doi.org/10.1111/dth.15963Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Roth N, Biedermann L, Fournier N, et al. Occurrence of skin manifestations in patients of the Swiss inflammatory bowel disease cohort study. PLoS One. 2019; 14(1):e0210436. 10.1371/journal.pone.0210436 CASPubMedWeb of Science®Google Scholar 2Antonelli E, Bassotti G, Tramontana M, et al. Dermatological manifestations in inflammatory bowel diseases. J Clin Med. 2021; 10(2): 364. 10.3390/jcm10020364 CASPubMedWeb of Science®Google Scholar 3Turkcapar N, Toruner M, Soykan I, et al. The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease. Rheumatol Int. 2006; 26(7): 663-668. 10.1007/s00296-005-0044-9 PubMedWeb of Science®Google Scholar 4Yamanaka H, Tanaka Y, Takeuchi T, et al. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther. 2016; 18: 34. 10.1186/s13075-016-0932-2 PubMedWeb of Science®Google Scholar 5Suzuki Y, Watanabe M, Matsui T, et al. Tofacitinib as induction and maintenance therapy in Japanese patients with active ulcerative colitis. Inflamm Intest Dis. 2019; 4(4): 131-143. 10.1159/000502144 PubMedGoogle Scholar 6Liu J, Hou Y, Sun L, et al. A pilot study of tofacitinib for refractory Behcet's syndrome. Ann Rheum Dis. 2020; 79(11): 1517-1520. 10.1136/annrheumdis-2020-217307 CASPubMedWeb of Science®Google Scholar 7O'Shea JJ, Gadina M. Selective Janus kinase inhibitors come of age. Nat Rev Rheumatol. 2019; 15(2): 74-75. 10.1038/s41584-018-0155-9 PubMedWeb of Science®Google Scholar 8Polycarpou A, Walker SL, Lockwood DN. A systematic review of immunological studies of erythema nodosum leprosum. Front Immunol. 2017; 8: 233. 10.3389/fimmu.2017.00233 PubMedWeb of Science®Google Scholar 9Strober BE, Gottlieb AB, van de Kerkhof PCM, et al. Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials. Br J Dermatol. 2019; 180(1): 67-75. 10.1111/bjd.17149 CASPubMedWeb of Science®Google Scholar Volume35, Issue12December 2022e15963 ReferencesRelatedInformation